Home › Prostate Cancer › NCT06675357
Using FAPI PET/MRI to Evaluate Prostate Cancer
Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18 years or older * Able and willing to provide informed consent * Known diagnosis of prostate cancer * Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET * Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases. * Willing and able to undergo PET/MRI as part of this research Exclusion Criteria: * Unable or unwilling to provide informed consent * Contraindication(s) to or inability to undergo PET/MRI * Participants for whom PET/MRI will delay timely delivery of treatment * Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met: * Have their own prescription for the medication * The informed consent process is conducted prior to the self-administration of this medication * Come to the research visit with a driver
About the study
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer.
Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
What is being tested
- FAPI (radiation)
- Positron Emission Tomography (PET) (procedure)
- Magnetic Resonance Imaging (procedure)
Sponsor: University of Wisconsin, Madison · Participants: 30 · Started: Feb 27, 2026
Contact the study team
- Radiology Studies · Phone: 608-282-8349
Official record on ClinicalTrials.gov — NCT06675357
Locations in the U.S.
| Wisconsin | University of Wisconsin, Madison |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.